Acute myocardial infarction associated wiht Sildenafil (Viagra) ingestion.

[1]  I. Goldstein,et al.  Oral sildenafil in the treatment of erectile dysfunction. 1998. , 1998, The Journal of urology.

[2]  A. Agarwal,et al.  Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). , 1999, Urology.

[3]  S. Wolfe,et al.  Safety of sildenafil citrate , 1998, The Lancet.

[4]  Conti Cr.  VIAGRA, THE LATEST CARDIO-VASCULAR DRUG , 1998 .

[5]  R. A. Murphy,et al.  Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. , 1998, The Journal of urology.

[6]  S. Ballard,et al.  Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile dysfunction in the anesthetized dog. , 1998, The Journal of urology.

[7]  S. Ballard,et al.  Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. , 1998, The Journal of urology.

[8]  A. Morales,et al.  Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunction , 1998, International Journal of Impotence Research.

[9]  Tom F. Lue,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.

[10]  G. Wagner,et al.  Fortnightly review: Update on male erectile dysfunction , 1998, BMJ.

[11]  A. Burnett.  Nitric oxide in the penis: physiology and pathology. , 1997, The Journal of urology.

[12]  J C Gingell,et al.  Sildenafil, a novel effective oral therapy for male erectile dysfunction. , 1996, British journal of urology.

[13]  G. Muirhead,et al.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. , 1996, International journal of impotence research.

[14]  K. Andersson,et al.  Physiology of penile erection. , 1995, Physiological reviews.

[15]  L. Ignarro,et al.  Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission , 1992 .